Indegene Ltd

Indegene Ltd has announced that its Board of Directors will convene on July 30, 2026. The primary agenda items include the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The meeting will also address the allotment of shares under the RSU Scheme 2020 and ESOP Scheme 2020. The trading window for securities will remain closed from July 1, 2026, until 48 hours after the declaration of the financial results.

Indegene Ltd has announced the closure of its trading window effective July 01, 2026, in compliance with SEBI regulations and its internal code of conduct. This closure is in preparation for the finalization and approval of the company's standalone and consolidated financial results for the quarter ending June 30, 2026. The trading window will reopen 48 hours after the financial results are officially declared and disseminated to the stock exchanges. All designated persons and insiders are advised against trading in the company's securities during this period.

Indegene Ltd has received an assessment order under Section 143(3) read with 144C(3) read with 144B of the Income Tax Act, 1961 for the Assessment Year 2023-24 (corresponding to the Financial Year 2022-23), resulting in an income tax demand of ₹43,68,84,410 (including interest). The demand arises from transfer pricing adjustments made by the Income Tax Authority. Indegene believes its positions are well-supported and is pursuing resolution through the Mutual Agreement Procedure (MAP) under the Double Taxation Avoidance Agreement (DTAA) between India & USA, while also exploring domestic appellate remedies. The company does not expect any material adverse impact on its financial position or operations.

Indegene has been recognized as a Leader in the ISG Provider Lens™ for Life Sciences Digital Services in Commercial Operations – Digital Evolution (Service Providers) Quadrant 2026. The assessment highlights Indegene’s domain expertise, technology platforms, and use of AI and GenAI. ISG's report evaluates service providers based on their ability to modernize commercial operations for biopharmaceutical, biotech, and medical technology companies. This is the 3rd consecutive year ISG has recognized Indegene.

Indegene Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹2.25 per equity share for the financial year ended March 31, 2026, which will be paid within 30 days after shareholder approval at the ensuing Annual General Meeting. Additionally, the board approved allotments under the ESOP Scheme 2020 and RSU Scheme 2020. Significant amendments were also approved for 19 policies under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015, covering areas like material subsidiary, whistle-blower, insider trading, related party transactions, and corporate governance.

Indegene Ltd has announced the opening of its trading window for Designated Persons, effective Saturday, May 2, 2026. This decision follows the approval and declaration of the company's financial results for the quarter and year ended March 31, 2026. In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct, Designated Persons, their immediate relatives, and other Insiders are now permitted to trade in the company's equity shares until further communication. The intimation will also be posted on the company's website.

Indegene Ltd. has submitted the Monitoring Agency Report for the quarter ended March 31, 2026, as mandated by SEBI regulations. The report, issued by CARE Ratings Limited (Care Edge Ratings), monitors the utilization of proceeds from the company's Initial Public Offering (IPO) of ₹760.00 crores. The report confirms "NIL" deviation from the objects disclosed in the Offer Document and states that all utilization is as per the disclosures. The company also confirmed that shareholder approval was obtained in case of any material deviations, though none were reported.

Indegene Ltd's Board of Directors, at its meeting on April 29, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board also recommended a final dividend of ₹2.25 per equity share (face value ₹2/-) for the financial year 2025-26, which will be paid within 30 days of shareholder approval at the upcoming Annual General Meeting. Additionally, the Board approved allotments under the ESOP Scheme 2020 and RSU Scheme 2020, and sanctioned amendments to various policies under SEBI regulations, including those related to material subsidiaries, whistleblowers, insider trading, related party transactions, and corporate governance.

Indegene Ltd reported strong financial results for Q4 and the full year ended March 31, 2026. In Q4 FY26, revenue grew 32.8% year-over-year to ₹10,034 million (USD 109.7 million), marking the first time quarterly revenue crossed ₹1,000 crore. Adjusted EBITDA for the quarter was ₹1,889 million, with an 18.8% margin. For the full fiscal year 2026, the company achieved a revenue of ₹35,105 million (USD 396.9 million), representing a 23.6% YoY growth. Full-year adjusted EBITDA stood at ₹6,793 million with a 19.4% margin. Cash flow from operations significantly increased by 47.3% YoY to ₹6,508 million. The Board also recommended a final dividend of ₹2.25 per equity share for FY26, a 12.5% increase from FY25. The company highlighted strong client relationships, with 53 clients contributing over $1 million in annual revenue, and breakthrough GenAI-led wins.

Indegene Ltd's Board of Directors met on April 29, 2026, and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of ₹2.25 per equity share (face value ₹2) for FY26, which will be paid within 30 days of shareholder approval at the upcoming AGM. Additionally, the Board approved allotments under the ESOP Scheme 2020 and RSU Scheme 2020, and sanctioned amendments to nineteen policies in compliance with SEBI regulations, covering areas like material subsidiary, whistle blower, insider trading, related party transactions, and corporate governance.